Mikhail Blagosklonny is a prominent professor of oncology at the renowned Roswell Park Cancer Institute in New York. He is a known scientist who studies Aging and Cancers. Mikhail has facilitated the development of anti-cancer methods as well as cancer prevention and therapy methods. Moreover, his captivating interests in research are in cellular and molecular biological as well as medical investigation. They include anti-cancer therapeutic, signal transduction, fresh cancer strategies, mitosis, and apoptosis.
Mikhail Blagosklonny has also formulated a hypothesis about the probable role of TOR signaling in cancer and aging. He recommended the use of rapamycin, a popular medicine that acts as a potential treatment for cancer. Scientists are investigating his claims about the treatment. However, Mikhail remains optimistic about the success of rapamycin. Moreover, he is among the most passionate advocates of the medicine in longevity research. Visit classroomvoices.org to read more about Mikhail.
Academic and Career Profile
Mikhail Blagosklonny studied at the First Pavlov State Medical University in St. Petersburg where he earned his master’s degree in internal medicine. Additionally, Mikhail was awarded a Ph.D. in cardiology and experimental medicine from the institution.
His Career journey started when he became an associate professor at the New York Medical College in 2002. Later, Mikhail Blagosklonny became a top scientist at the renowned Ordway Research Institute in Albany. In 2009, he became a professor of oncology at the Roswell Park Cancer Institute.
Achievements of Mikhail Blagosklonny
Mikhail Blagosklonny is a well-known author of over 260 articles that have been published in peer-reviewed journals. Further, Mikhail is an author of the theory of aging hyperfunction, chemotherapeutic engineering, and cell cyclotherapy. Researchers have cited his articles more than 25,000 times. This has earned Mikhail an h-index of 83.
Currently, he is an associate editor of Cell Death Differentiation and Cancer Biology Therapy. Moreover, Mikhail has served on the editorial panel of Cancer Research, Autophagy, International J Cancer, and PLOS ONE. He is also an editor-in-chief of Cell Cycle, Aging, and Oncotarget.
Conclusively, the unwavering commitment of Mikhail in oncology has made him popular and among the best oncology researchers worldwide. He cites that he is driven by his love for people and the vision of living in a disease-free society. Visit ResearchGate.Net to learn more about Mikhail’s latest work.